Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Shares Acquired by BML Capital Management LLC

BML Capital Management LLC boosted its position in shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST) by 3.0% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,136,091 shares of the company’s stock after purchasing an additional 33,196 shares during the period. Milestone Pharmaceuticals makes up 1.0% of BML Capital Management LLC’s portfolio, making the stock its 16th biggest position. BML Capital Management LLC owned 2.13% of Milestone Pharmaceuticals worth $1,727,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in the company. BNP Paribas Financial Markets grew its holdings in Milestone Pharmaceuticals by 177.0% during the 1st quarter. BNP Paribas Financial Markets now owns 16,900 shares of the company’s stock worth $30,000 after acquiring an additional 10,800 shares in the last quarter. Lion Point Capital LP grew its holdings in Milestone Pharmaceuticals by 1.7% during the 2nd quarter. Lion Point Capital LP now owns 2,340,207 shares of the company’s stock worth $3,089,000 after acquiring an additional 40,000 shares in the last quarter. Valeo Financial Advisors LLC grew its holdings in Milestone Pharmaceuticals by 100.0% during the 3rd quarter. Valeo Financial Advisors LLC now owns 20,000 shares of the company’s stock worth $30,000 after acquiring an additional 10,000 shares in the last quarter. Finally, Atria Investments Inc grew its holdings in Milestone Pharmaceuticals by 44.4% during the 3rd quarter. Atria Investments Inc now owns 40,421 shares of the company’s stock worth $61,000 after acquiring an additional 12,430 shares in the last quarter. 86.18% of the stock is owned by institutional investors and hedge funds.

Milestone Pharmaceuticals Stock Performance

Shares of MIST traded down $0.02 during midday trading on Tuesday, hitting $1.92. 67,554 shares of the stock traded hands, compared to its average volume of 226,993. The business’s 50 day moving average price is $1.52 and its two-hundred day moving average price is $1.51. The firm has a market capitalization of $102.28 million, a PE ratio of -1.90 and a beta of 1.72. The company has a debt-to-equity ratio of 1.61, a quick ratio of 19.13 and a current ratio of 19.13. Milestone Pharmaceuticals Inc. has a 1-year low of $1.12 and a 1-year high of $3.52.

Analysts Set New Price Targets

MIST has been the subject of several recent analyst reports. HC Wainwright reissued a “buy” rating and set a $25.00 price objective on shares of Milestone Pharmaceuticals in a report on Monday, October 14th. Rodman & Renshaw began coverage on shares of Milestone Pharmaceuticals in a research report on Thursday, August 22nd. They set a “buy” rating and a $9.00 price objective for the company.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.